Advertisement

Osteoporosis International

, Volume 20, Issue 4, pp 507–518 | Cite as

Risk factors for low BMD in healthy men age 50 years or older: a systematic review

  • A. Papaioannou
  • C. C. Kennedy
  • A. Cranney
  • G. Hawker
  • J. P. Brown
  • S. M. Kaiser
  • W. D. Leslie
  • C. J. M. O’Brien
  • A. M. Sawka
  • A. Khan
  • K. Siminoski
  • G. Tarulli
  • D. Webster
  • J. McGowan
  • J. D. Adachi
Review

Abstract

Summary

In this systematic review, we summarize risk factors for low bone mineral density and bone loss in healthy men age 50 years or older. Consistent risk factors were: age, smoking, low weight, physical/functional limitations, and previous fracture. Data specific to men has clinical and policy implications.

Introduction

Osteoporosis is a significant health care problem in men as well as women, yet the majority of evidence on diagnosis and management of osteoporosis is focused on postmenopausal women. The objective of this systematic review is to examine risk factors for low bone mineral density (BMD) and bone loss in healthy men age 50 years or older.

Materials and methods

A systematic search for observational studies was conducted in MEDLINE, Cochrane Database of Systematic Reviews, DARE, CENTRAL, CINAHL and Embase, Health STAR. The three main search concepts were bone density, densitometry, and risk factors. Trained reviewers assessed articles using a priori criteria.

Results

Of 642 screened abstracts, 299 articles required a full review, and 25 remained in the final assessment. Consistent risk factors for low BMD/bone loss were: advancing age, smoking, and low weight/weight loss. Although less evidence was available, physical/functional limitations and prevalent fracture (after age 50) were also associated with low BMD/bone loss. The evidence was inconsistent or weak for physical activity, alcohol consumption, calcium intake, muscle strength, family history of fracture/osteoporosis, and height/height loss.

Conclusion

In this systematic review, we identified several risk factors for low BMD/bone loss in men that are measurable in primary practice.

Keywords

Bone density DXA Men Osteoporosis Risk factors Systematic review 

Notes

Acknowledgments

We thank Chistina Lachetti, Kristina Szabo, and Nicole Zytaruk for data abstraction, and Lois Wyndham for literature review and library assistance.

This project was funded by the Ontario Ministry of Health and Long-Term Care, Ontario Osteoporosis Strategy.

Conflicts of interest

Alexandra Papaioannou, MD, FRCPC, MSc

Consulting and Advisory Role: Amgen, Eli Lilly, Merck Frosst, Novartis, Proctor & Gamble, Sanofi-aventis, Servier

Clinical Trials: Amgen, Eli Lilly, Merck, Novartis, Proctor & Gamble, Sanofi-aventis

Ann Cranney, MD, FRCPC, MSc has received honoraria for educational lectures from Merck Frosst, Alliance for Bone Health and Novartis; and consultant fees from Amgen Canada and Research funding from Hofmann La Roche.

Jacques P. Brown, MD, FRCPC has received honoraria for lecturing, consultancies, grants and research support for clinical trials: Abbott, Alpharx, Amgen, Arthrolab, Sanofi-aventis Canada, Boehringer Ingelheim/Roche, Bristol-Myers Squibb, Celltech, Eli Lilly Canada, Genizon, Glaxosmithkline, Merck Frosst, Nicox, Novartis, NPS Pharma, Pfizer, Proctor & Gamble, Quintiles, Rhône-Poulenc Rorer, Servier, Wyeth, Zelos.

Stephanie M Kaiser, MD, FRCPC

Advisory Boards: Amgen, Eli Lilly, Novartis, Wyeth-Ayerst, Servier

Speaker for: Amgen, Eli Lilly, Novartis, Merck, Procter & Gamble/Sanofi-aventis, AstraZeneca, Servier

William D. Leslie, MD, FRCPC, MSc

Speaker fees, research honoraria, and unrestricted research grants: Merck Frosst Canada Ltd; research honoraria and unrestricted educational grants from The Alliance for Better Bone Health: Sanofi-aventis and Procter & Gamble Pharmaceuticals Canada, Inc.; unrestricted research grants from Novartis Pharmaceuticals Canada, Inc.; unrestricted educational grants from Genzyme Canada

Aliya Khan

Consulting Role: Proctor & Gamble, Merck Frosst, Novartis

Research: Proctor & Gamble, Merck Frosst, Servier, Amgen, Eli Lilly

Jonathan D. Adachi, MD

Consulting Role: Amgen; Astra Zeneca, Eli Lilly; GlaxoSmithKline; Merck Frosst; Novartis; Proctor & Gamble; Roche; Sanofi-aventis; Servier

Clinical Trials: Eli Lilly; GlaxoSmithKline; Merck; Novartis; Pfizer; Proctor & Gamble; Sanofi-aventis; Servier; Wyeth-Ayerst

Courtney C. Kennedy, MSc; Gillian Hawker MD, MSc, FRCPC; Anna M. Sawka MD, FRCPC, PhD; Kerry Siminoski, MD, FRCPC; David Webster, MD, FRCP; Jessie McGowan MLIS: No competing interests to declare.

References

  1. 1.
    World Health Organization (WHO) (2003) Prevention and management of osteoporosis. World Health Organization, Geneva No. 921Google Scholar
  2. 2.
    Tenenhouse A, Joseph L, Kreiger N et al (2000) Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 11:897–904PubMedCrossRefGoogle Scholar
  3. 3.
    Szulc P, Munoz F, Duboeuf F et al (2005) Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int 16:1184–1192PubMedCrossRefGoogle Scholar
  4. 4.
    Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings SR, Cawthon PM, Ensrud KE et al (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21:1550–1556PubMedCrossRefGoogle Scholar
  6. 6.
    Papaioannou A, Wiktorowicz ME, Adachi JD et al (2000) Mortality, independence in living, and re-fracture, one year following hip fracture in Canadians. J Obstet Gynaecol Can 22:591–597Google Scholar
  7. 7.
    de Laet CE, van Hout BA, Burger H et al (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315:221–225PubMedGoogle Scholar
  8. 8.
    Jackson SA, Tenenhouse A, Robertson L (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11:680–687PubMedCrossRefGoogle Scholar
  9. 9.
    Center JR, Nguyen TV, Schneider D et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882PubMedCrossRefGoogle Scholar
  10. 10.
    Endo Y, Aharonoff GB, Zuckerman JD et al (2005) Gender differences in patients with hip fracture: a greater risk of morbidity and mortality in men. J Orthop Trauma 19:29–35PubMedCrossRefGoogle Scholar
  11. 11.
    Osnes EK, Lofthus CM, Meyer HE et al (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567–574PubMedCrossRefGoogle Scholar
  12. 12.
    National Osteoporosis Foundation (NOF) (2008) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DCGoogle Scholar
  13. 13.
    Harris RP, Helfand M, Woolf SH et al (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20:21–35PubMedCrossRefGoogle Scholar
  14. 14.
    Yoshimura N, Hashimoto T, Morioka S et al (1998) Determinants of bone loss in a rural Japanese community: the Taiji Study. Osteoporos Int 8:604–610PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshimura N, Kinoshita H, Danjoh S et al (2002) Bone loss at the lumbar spine and the proximal femur in a rural Japanese community, 1990–2000: the Miyama study. Osteoporos Int 13:803–808PubMedCrossRefGoogle Scholar
  16. 16.
    Cheung EY, Ho AY, Lam KF et al (2005) Determinants of bone mineral density in Chinese men. Osteoporos Int 16:1481–1486PubMedCrossRefGoogle Scholar
  17. 17.
    Kung AW, Ho AY, Ross PD et al (2005) Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound. Osteoporos Int 16:849–855PubMedCrossRefGoogle Scholar
  18. 18.
    Lau EM, Leung PC, Kwok T et al (2006) The determinants of bone mineral density in Chinese men—results from Mr. Os (Hong Kong), the first cohort study on osteoporosis in Asian men. Osteoporos Int 17:297–303PubMedCrossRefGoogle Scholar
  19. 19.
    Lynn HS, Lau EM, Wong SY et al (2005) An osteoporosis screening tool for Chinese men. Osteoporos Int 16:829–834PubMedCrossRefGoogle Scholar
  20. 20.
    Cauley JA, Fullman RL, Stone KL et al (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16:1525–1537PubMedCrossRefGoogle Scholar
  21. 21.
    Hannan MT, Felson DT, Dawson-Hughes B et al (2000) Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 15:710–720PubMedCrossRefGoogle Scholar
  22. 22.
    Dennison E, Eastell R, Fall CH et al (1999) Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporos Int 10:384–391PubMedCrossRefGoogle Scholar
  23. 23.
    Burger H, de Laet CE, van Daele PL et al (1998) Risk factors for increased bone loss in an elderly population: the Rotterdam Study. Am J Epidemiol 147:871–879PubMedGoogle Scholar
  24. 24.
    Knoke JD, Barrett-Connor E (2003) Weight loss: a determinant of hip bone loss in older men and women. The Rancho Bernardo Study. Am J Epidemiol 158:1132–1138PubMedCrossRefGoogle Scholar
  25. 25.
    Szulc P, Marchand F, Duboeuf F et al (2000) Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone 26:123–129PubMedCrossRefGoogle Scholar
  26. 26.
    Lunt M, Felsenberg D, Adams J et al (1997) Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 7:175–189PubMedCrossRefGoogle Scholar
  27. 27.
    Bendavid EJ, Shan J, Barrett-Connor E (1996) Factors associated with bone mineral density in middle-aged men. J Bone Miner Res 11:1185–1190PubMedGoogle Scholar
  28. 28.
    Orwoll ES, Bevan L, Phipps KR (2000) Determinants of bone mineral density in older men. Osteoporos Int 11:815–821PubMedCrossRefGoogle Scholar
  29. 29.
    Naves M, Diaz-Lopez JB, Gomez C et al (2005) Prevalence of osteoporosis in men and determinants of changes in bone mass in a non-selected Spanish population. Osteoporos Int 16:603–609PubMedCrossRefGoogle Scholar
  30. 30.
    Nguyen TV, Kelly PJ, Sambrook PN et al (1994) Lifestyle factors and bone density in the elderly: implications for osteoporosis prevention. J Bone Miner Res 9:1339–1346PubMedCrossRefGoogle Scholar
  31. 31.
    Kiel DP, Zhang Y, Hannan MT et al (1996) The effect of smoking at different life stages on bone mineral density in elderly men and women. Osteoporos Int 6:240–248PubMedCrossRefGoogle Scholar
  32. 32.
    Szulc P, Garnero P, Claustrat B et al (2002) Increased bone resorption in moderate smokers with low body weight: the Minos study. J Clin Endocrinol Metab 87:666–674PubMedCrossRefGoogle Scholar
  33. 33.
    May H, Murphy S, Khaw KT (1994) Cigarette smoking and bone mineral density in older men. QJM 87:625–630PubMedGoogle Scholar
  34. 34.
    Huuskonen J, Vaisanen SB, Kroger H et al (2000) Determinants of bone mineral density in middle aged men: a population-based study. Osteoporos Int 11:702–708PubMedCrossRefGoogle Scholar
  35. 35.
    Nguyen TV, Center JR, Eisman JA (2000) Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res 15:322–331PubMedCrossRefGoogle Scholar
  36. 36.
    Lunt M, Masaryk P, Scheidt-Nave C et al (2001) The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. Osteoporos Int 12:688–698PubMedCrossRefGoogle Scholar
  37. 37.
    May H, Murphy S, Khaw KT (1995) Alcohol consumption and bone mineral density in older men. Gerontology 41:152–158PubMedCrossRefGoogle Scholar
  38. 38.
    Looker AC, Beck TJ (2004) Maternal history of osteoporosis and femur geometry. Calcif Tissue Int 75:277–285PubMedCrossRefGoogle Scholar
  39. 39.
    Diamond TH, Higano CS, Smith MR et al (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100:892–899PubMedCrossRefGoogle Scholar
  40. 40.
    van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRefGoogle Scholar
  41. 41.
    Shahinian VB, Kuo YF, Freeman JL et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164PubMedCrossRefGoogle Scholar
  42. 42.
    Vestergaard P, Olsen ML, Paaske JS et al (2003) Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 254:486–493PubMedCrossRefGoogle Scholar
  43. 43.
    Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, Helfand M, and Oregon Health & Science University Evidence-based Practice Center (2001) Osteoporosis in postmenopausal women: diagnosis and monitoring. AHRQ Publication No. 01-E032 Agency for Healthcare Research and Quality, Rockville, MDGoogle Scholar
  44. 44.
    Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–34PubMedGoogle Scholar
  45. 45.
    Khan AA, Hodsman AB, Papaioannou A et al (2007) Management of osteoporosis in men: an update and case example. CMAJ 176:345–348PubMedGoogle Scholar
  46. 46.
    Siminoski K, Leslie WD, Frame H et al (2005) Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 56:178–188PubMedGoogle Scholar
  47. 47.
    De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338PubMedCrossRefGoogle Scholar
  48. 48.
    Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029–1037PubMedCrossRefGoogle Scholar
  49. 49.
    Kanis JA, Johansson H, Oden A et al (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 16:799–804PubMedCrossRefGoogle Scholar
  50. 50.
    Kanis JA, Johansson H, Johnell O et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742PubMedCrossRefGoogle Scholar
  51. 51.
    Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
  52. 52.
    Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162PubMedCrossRefGoogle Scholar
  53. 53.
    Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899PubMedCrossRefGoogle Scholar
  54. 54.
    Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRefGoogle Scholar
  55. 55.
    World Health Organization Collaborating Centre for Metabolic Bone Diseases (2008) WHO Fracture Risk Assessment Tool (FRAX). www.shef ac uk/FRAX/
  56. 56.
    Orwoll E, Blank JB, Barrett-Connor E et al (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • A. Papaioannou
    • 1
    • 16
  • C. C. Kennedy
    • 2
  • A. Cranney
    • 3
  • G. Hawker
    • 4
  • J. P. Brown
    • 5
  • S. M. Kaiser
    • 6
  • W. D. Leslie
    • 7
  • C. J. M. O’Brien
    • 8
  • A. M. Sawka
    • 9
  • A. Khan
    • 10
  • K. Siminoski
    • 11
  • G. Tarulli
    • 12
  • D. Webster
    • 13
  • J. McGowan
    • 14
  • J. D. Adachi
    • 15
  1. 1.Division of Geriatric Medicine, Department of MedicineMcMaster UniversityHamiltonCanada
  2. 2.Department of MedicineMcMaster UniversityHamiltonCanada
  3. 3.Division of RheumatologyUniversity of Ottawa, Scientist, Clinical Epidemiology, Ottawa Health Research InstituteOttawaCanada
  4. 4.Women’s College Hospital, Departments of Medicine and Health Policy, Management and EvaluationUniversity of TorontoTorontoCanada
  5. 5.Department of MedicineUniversité Laval and Head of the Division of Rheumatology at Le Centre Hospitalier Universitaire de QuébecQuebecCanada
  6. 6.Division of Endocrinology, Department of MedicineDalhousie UniversityHalifaxCanada
  7. 7.Department of RadiologyUniversity of ManitobaWinnipegCanada
  8. 8.Department of Nuclear Medicine, Brantford General HospitalBrantfordCanada
  9. 9.Division of Endocrinology, Department of MedicineUniversity Health Network, University of TorontoTorontoCanada
  10. 10.Division of Endocrinology and Geriatrics, Department of MedicineMcMaster UniversityHamiltonCanada
  11. 11.Department of Radiology and Diagnostic Imaging and Division of Endocrinology and Metabolism, Department of Internal MedicineUniversity of AlbertaEdmontonCanada
  12. 12.Department of Medical ImagingHumber Regional HospitalTorontoCanada
  13. 13.Department of Nuclear MedicineSudbury Regional HospitalSudburyCanada
  14. 14.Institute of Population Health, Adjunct Professor, Department of MedicineUniversity of OttawaOttawaCanada
  15. 15.Alliance for Better Bone Health Chair in Rheumatology, Department of MedicineMcMaster UniversityHamiltonCanada
  16. 16.McMaster University, Hamilton Health SciencesHamiltonCanada

Personalised recommendations